| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2006;37:2168.)
© 2006 American Heart Association, Inc.
Case Reports |
From the Department of Neurology (K.M.W., A.T.), University of Illinois at Peoria; and the OSF Stroke Center and Network (M.M., D.W.), Illinois Neurological Institute, OSF St. Francis Medical Center, Peoria, Ill.
Correspondence to Kathleen M. Wiese, DO, University of Illinois at Peoria, OSF St. Francis Medical Center, Department of Neurology, 530 NE Glen Oak Ave, Peoria, IL 61637. E-mail kathleenwiese{at}yahoo.com
Abstract
Background and Purpose Historically, the use of tissue plasminogen activator (tPA) thrombolysis in pregnancy has been regarded as relatively contraindicated. Underlying this stance has been the concern over the risk of bleeding complications in both mother and child.
Summary of Case We report the successful use of intravenous recombinant tPA (rtPA) thrombolysis in a pregnant woman with acute cardioembolic stroke.
Conclusions The patient improved clinically, did not develop complications after receiving rtPA, and at 37 weeks gestation, delivered a healthy infant, demonstrating that rtPA thrombolysis may be used safely in pregnant women.
Key Words: thrombolysis tissue plasminogen activator
This article has been cited by other articles:
![]() |
J. De Keyser, Z. Gdovinova, M. Uyttenboogaart, P. C. Vroomen, and G. J. Luijckx Intravenous Alteplase for Stroke: Beyond the Guidelines and in Particular Clinical Situations Stroke, September 1, 2007; 38(9): 2612 - 2618. [Abstract] [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |